10x Genomics is a life science technology company. Co.'s integrated platform solutions include instruments, consumables and software. Co.'s commercial product portfolio utilizes its Chromium X Series and Chromium Connect, its Visium CytAssist, an instrument designed to simplify the Visium solution workflow, its Xenium Analyzer, an instrument designed for high-throughput analysis of cells in their tissue environment, and its proprietary microfluidic chips, slides, reagents and other consumables for its Chromium, Visium and Xenium solutions. Co. bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The TXG stock yearly return is shown above.
The yearly return on the TXG stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TXG annual return calculation with any dividends reinvested as applicable (on ex-dates).
|